FindMyKOL
Clinical trialNCT03074318TerminatedPhase 1/2Interventional

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

NCT03074318 is a phase 1/2 interventional trial sponsored by Fred Hutchinson Cancer Center. As of 21 Nov 2026, it was terminated. It studies Avelumab and Trabectedin in Metastatic Leiomyosarcoma, Metastatic Liposarcoma and 2 more conditions. The registry lists an enrollment of 35 participants at 1 site in 1 country. The registry lists a start date of 28 Sept 2017 and a primary completion date of 15 Nov 2020. One of its registered investigators has a FindMyKOL profile.

SponsorFred Hutchinson Cancer Center →Enrollment35Metastatic LeiomyosarcomaMetastatic LiposarcomaUnresectable LeiomyosarcomaUnresectable Liposarcoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03074318
FieldValue
Registry IDNCT03074318
StatusTerminated
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorFred Hutchinson Cancer Center
Enrollment35
Registered sites1
Countries1
ConditionsMetastatic Leiomyosarcoma, Metastatic Liposarcoma, Unresectable Leiomyosarcoma and Unresectable Liposarcoma
DrugsAvelumab and Trabectedin
Start28 Sept 2017
Primary completion15 Nov 2020
Study completion15 Nov 2020
Last update posted29 Apr 2022

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I/II studies the side effects of avelumab and trabectedin and how well they work in treating patients with leiomyosarcoma or liposarcoma that has spread to other places in the body (metastatic) or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving avelumab and trabectedin may work better in treating patients with liposarcoma or leiomyosarcoma.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Washington, United States1 site
  • Fred Hutch/university of Washington Cancer Consortium

    Seattle

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashington: 1 siteWA1MontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03074318

Each answer restates registry values shown on this page.

What is NCT03074318?

NCT03074318 is a phase 1/2 interventional trial sponsored by Fred Hutchinson Cancer Center. It studies Avelumab and Trabectedin in Metastatic Leiomyosarcoma, Metastatic Liposarcoma and 2 more conditions.

Who leads NCT03074318?

The registry names Seth Pollack (principal investigator, Northwestern University) as the overall official.

Where does NCT03074318 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03074318 study?

The registered drug and biological interventions are Avelumab and Trabectedin.

When did NCT03074318 end?

The registry lists a primary completion date of 15 Nov 2020 and a study completion date of 15 Nov 2020. The sponsor last updated the record on 29 Apr 2022.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.